Your browser doesn't support javascript.
loading
LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy.
Ibrahim, Rebecca; Saleh, Khalil; Chahine, Claude; Khoury, Rita; Khalife, Nadine; Cesne, Axel Le.
Afiliación
  • Ibrahim R; International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
  • Saleh K; International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
  • Chahine C; International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
  • Khoury R; International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
  • Khalife N; Department of head and neck Oncology, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
  • Cesne AL; International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
Biomedicines ; 11(7)2023 Jul 01.
Article en En | MEDLINE | ID: mdl-37509517
ABSTRACT
One of the most important steps forward in the management of cancer was the discovery of immunotherapy. It has become an essential pillar in the treatment paradigm of cancer patients. Unfortunately, despite the various options presented with immune checkpoint inhibitors (ICIs), the benefit is still limited to select patients and the vast majority of these patients gain either minimal benefit or eventually progress, leaving an unmet need for the development of novel therapeutic agents and strategies. Lymphocyte activation gene-3 (LAG-3), an immune checkpoint receptor protein, is a molecule found on the surface of activated T-cells. It plays a major role in negatively regulating T-cell function thereby providing tumors with an immune escape in the tumor microenvironment (TME). Given its importance in regulating the immune system, LAG-3 has been considered as a promising target in oncology and precision medicine. To date, two LAG-3-directed agents (eftilagimod alpha and relatlimab) have been approved in combination with programmed death-1 (PD-1) inhibitors in the setting of advanced solid tumors. In this review, we discuss the structure of LAG-3, its mechanism of action, and its interaction with its ligands. We also shed light on the emerging treatments targeting LAG-3 for the treatment of solid tumors.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2023 Tipo del documento: Article País de afiliación: Francia